Loading
Latest filing published 04 Oct 2023 for Fresh Tracks Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Andrew D. Sklawer in Fresh Tracks Therapeutics, Inc., where the filings describe the role as chief executive. The record holds 2 filings, for trades running from 17 May 2021 to 2 October 2023.
No open-market sale appears; the market trades are 1 purchase worth €10k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 option exercise.
The latest filing, published on 4 October 2023, reports an option exercise in Fresh Tracks Therapeutics, Inc. The last insider purchase was made public on 19 May 2021, 1,979 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations